Additionally, the cleavage of native GLP-1 (7-36) by alternative pathways such as NEP 24.11 into metabolites may account for some of the cardiovascular benefits of native GLP-1 either directly or indirectly, by correcting metabolic syndrome (Tomas et al., 2011c, 2015). The gene discussed is GCG; the disease is metabolic syndrome.